KRT14 and breast cancer: Olaparib-treated macrophages, but not control macrophages, were able to ingest GFP-labeled K14-Cre BRCA1f/fp53f/f BC cells (Figures 2C and S2B), indicative of a functional change toward an anti-tumor phenotype.